Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector

Degui Wang, Zhiping Wang, Junqiang Tian, Xiangdong He, Wasim H. Chowdhury, Xiangbo Zhang, Shigang Li, Ronald Rodriguez

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Purpose: To construct a dual specific vector which contains prostate stem cell antigen enhancer (PSCAE) and uroplakin II (UPII) promoter targeted bladder cancer. Methods: UPII promoter and PSCAE were amplified by polymerase chain reaction (PCR). Luciferase gene (LUC) was obtained from plasmid pBK-CMV-LUC. PSCAE, UPII promoter and LUC were inserted into shuttle plasmid to create Rp-UPII-LUC and Rp-PSCAE-UPII-LUC. Rp-UPII-LUC and Rp-PSCAE-UPII-LUC were cotransfected with pCMV-β-gal into various cell lines at the presence or absence of androgen receptor agonist R1881 and androgen receptor antagonist flutamide. Luminescence was detected with luciferase assay kit and counted on liquid scintillation counter. Results: Bladder cancer cells showed higher LUC activity than non-bladder cancer cells after transfected with plasmids Rp-UPII-LUC and Rp-PSCAE-UPII-LUC. PSCAE could improve the LUC activity in both AR positive and AR negative bladder cancer cells but not in non-bladder cancer cells and normal human urothelial (NHU) cells. R1881 could increase the LUC activity in AR positive bladder cancer cells but not in AR negative bladder cancer cells and non-bladder cancer cells. Flutamide could not inactivate PSCAE in bladder cancer cells. Conclusions: PSCAE can improve target gene expression in bladder cancer cells but not in non-bladder cancer cells and NHU cells. PSCAE maintains a certain level of androgen independent activity in bladder cancer cells. PSCAE is active in both AR positive and AR negative bladder cancer cells. The results suggest that combination of PSCAE with UPII promoter is feasible in constructing bladder cancer-specific vectors.

Original languageEnglish (US)
Pages (from-to)164-169
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume28
Issue number2
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Keywords

  • Bladder cancer
  • Gene therapy
  • Prostate stem cell antigen enhancer
  • Uroplakin II promoter

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector'. Together they form a unique fingerprint.

Cite this